Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07280585 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

Study acronym: STOP-PKD
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 28 of 30 sitesv6
  2. Trial sites expanded: 27 → 30 locationsv5
  3. Site details revised at 12 of 27 sitesv4
  4. Site details revised at 1 of 27 sitesv3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 11, 2025 to Dec 16, 2025
    • Site details revised at 27 of 27 sites
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria. This trial tests if the SGLT2-inhibitor dapagliflozin slows down the loss of kidney function in ADPKD.
Trial Details
NCT Number NCT07280585
Lead Sponsor University of Cologne
Collaborators: German Research Foundation
Conditions
(from sponsor)		 Polycystic Kidney, Autosomal Dominant
Related terms Polycystic Kidney Diseases, Polycystic Kidney, Autosomal Dominant
Enrollment 420 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov